Monday, October 5, 2026
ExploreSearch
Via News
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Press releaseGlobeNewswire· February 9, 2026

WISeKey’s WISe.Art and GMA Once Again Revolutionize the Future of Art and Technology in an Extraordinary Event in Venice

View original at globenewswire.com
WISeKey’s WISe.Art and GMA Once Again Revolutionize the Future of Art and Technology in an Extraordinary Event in Venice WISeKey’s WISe.Art and GMA Once Again Revolutionize the Future of Art and Technology in an Extraordinary Event in Venice Geneva, Switzerland, February 9, 2026 – WISeKey International Holding Ltd (“WI…
Opening lines of the source · GlobeNewswire · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • The technologies do not replace the artist, but rather amplify creative capacity, protect artworks, and enable global dissemination

    80% confidence

  • Post-quantum cryptography leveraging SEALSQ's quantum-resistant technologies future-proofs artworks against the next generation of cyber threats and quantum computing attacks

    80% confidence

  • WISe.ART is built on WISeKey's deep expertise in cybersecurity, digital identity, and blockchain technologies offering a secure and sovereign NFT ecosystem

    80% confidence

  • Venice will become the global laboratory of a new creative era, where technological innovation is placed at the service of artistic expression and human values

    80% confidence

  • The future of art passes through technology, but remains profoundly human

    80% confidence

  • WISeSat constellation enables art projects that are globally accessible, resilient, and independent of traditional terrestrial networks

    80% confidence

Cited in these Via News reports

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Pharma Pipeline Catalysts and M&A Heat Up as AI-Designed Drugs Enter the Clinic
Late-September 2026 brought a dense run of clinical readouts: Novo Nordisk's CagriSema data at EASD, Lilly's ADtouch results for EBGLYSS, and Merck's tulisokibart Phase 2b result. Lilly's $2.9B Merida Biosciences acquisition and the 2026-11-14 FDA PDUFA date for ivonescimab sit alongside these as the main deal and regulatory events. AI-designed drugs such as rentosertib, and speculative AI-linked trial ventures such as QAIAx, are moving from hype toward clinical validation. Broader AI-sector regulatory and legal friction (Tesla Cybercab probe, xAI Minnesota ruling, OpenAI lawsuits) shows rising scrutiny that could spill into AI-driven healthcare.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,985
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,985 facts checked against source5,340 source documents archived
Query this data → isubstrate.com